Stockscreener 앱 받기
6.97
3.73%
-0.27
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Trading Action: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum - Defense World
CVKD SEC FilingsCadrenal Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Cadrenal Therapeutics, Inc. (CVKD) stock: surges on breakthrough 12-LOX diabetes research - parameter.io
Cadrenal Therapeutics Inc. (CVKD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Trading the Move, Not the Narrative: (CVKD) Edition - Stock Traders Daily
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Sahm
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data - TradingView
CVKD: CAD-1005 advances to phase III for HIT, targeting a major unmet need with strong regulatory support - TradingView
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease - TipRanks
Cadrenal Therapeutics (CVKD) spotlights CAD-1005 12-LOX data in obesity, diabetes and HIT - Stock Titan
Trend Recap: What is Cadrenal Therapeutics Incs valuation compared to sector2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Cadrenal Therapeutics Inc expected to post a loss of $1.16 a shareEarnings Preview - TradingView
CVKD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday - Defense World
CVKDCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - ADVFN Ltd
Cadrenal schedules FDA meeting for HIT drug CAD-1005 - Investing.com India
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewswire
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - Defense World
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
CVKD Should I Buy - Intellectia AI
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial - Investing.com India
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Yahoo Finance
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial By Investing.com - Investing.com Canada
Cadrenal Therapeutics stock surges on Phase 2 trial results - Investing.com South Africa
Cadrenal Therapeutics' recent acquisition makes progress toward phase 3 trial - The Business Journals
Cadrenal Therapeutics stock surges on Phase 2 trial results By Investing.com - Investing.com Nigeria
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005 - TipRanks
Cadrenal Therapeutics Inc recently received approval from the U.S. Food and Drug Administration (FDA) to hold an end-of-Phase II clinical trial meeting. - Bitget
Cadrenal Therapeutics announces phase 2 results for CAD-1005 - marketscreener.com
Cadrenal Therapeutics Reports Over 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Trial for Heparin-Induced Thrombocytopenia - Quiver Quantitative
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - Bitget
Cadrenal Therapeutics reports Phase 2: CAD-1005 cuts thrombotic events >25% vs placebo; EOP2 meeting set - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results For CAD-1005 - TradingView
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
Smart Money: What is Cadrenal Therapeutics Incs valuation compared to sector2025 Support & Resistance & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Cadrenal Therapeutics expands at-the-market stock offering capacity - MSN
What is Cadrenal Therapeutics Inc. s revenue forecastJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - mfd.ru
Trading Recap: Can Cadrenal Therapeutics Inc. stock double in the next yearDollar Strength & Daily Growth Stock Investment Tips - mfd.ru
CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT) - Yahoo Finance
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - Intellectia AI
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 22.1% in January - Defense World
Can Cadrenal Therapeutics Inc. weather a recessionJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Is Cadrenal Therapeutics Inc. stock a safe haven assetWeekly Trend Report & Smart Allocation Stock Tips - mfd.ru
Fed Meeting: Can Cadrenal Therapeutics Inc stock double in the next yearIndex Update & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.4% – What’s Next? - Defense World
(CVKD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Profit Review: Will Cadrenal Therapeutics Inc outperform its industry peersMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Update Recap: Will Cadrenal Therapeutics Inc outperform its industry peersJuly 2025 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):